Alcon Inc. (ALC) Stock Price & Analysis
Alcon Inc. (ALC) closed at USD 70.63 on Thursday, October 22, 2026, up 4.75% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 67.43; the Oct 22, 2026 session ranged USD 68–70.68 on volume of 2,207,898 shares. Market capitalization is $34.14B, with a 52-week range of USD 61.84–87.64 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 10:01 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ALC.md
Key facts (ALC)
- 2 of 80 tracked superinvestors hold ALC (13F, Q2 2026): 0 new, 2 added, 0 reduced, 0 unchanged.
- Analysts: Buy (mean 2.15 on a 1–5 scale) (27 analysts), mean target USD 82.73 (range 62–103).
- Total return with dividends: 1Y -6.9% vs S&P 500 +14.9%; 5Y -12.2% vs S&P 500 +80.3%.
- Next earnings: 2026-11-10, EPS estimate USD 0.89, revenue estimate $2.75B.
Superinvestors (SEC 13F-HR, Q2 2026) (ALC)
2 of 80 tracked investors hold ALC. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| AKO Capital | 15.19% | $652M | Added +3.8% | |
| Lee Ainslie | Maverick Capital | 0.02% | $2.2M | Added +159.5% |
Analysts (ALC)
Consensus Buy (mean 2.15 on a 1–5 scale), 27 analysts; mean target USD 82.73 (low 62, high 103).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-21 | Needham | Reiterated | Buy | $98 |
| 2026-10-12 | BTIG | Target lowered | Buy | $82 → $74 |
| 2026-10-07 | Barclays | Initiated | Equal-Weight | $70 |
| 2026-09-22 | Jefferies | Target lowered | Buy | $95 → $85 |
| 2026-09-15 | Needham | Reiterated | Buy | $98 |
| 2026-08-12 | JP Morgan | Target raised | Neutral | $77.53 → $78.4 |
| 2026-08-12 | Mizuho | Target raised | Outperform | $80 → $85 |
| 2026-08-11 | Needham | Target raised | Buy | $95 → $98 |
| 2026-08-11 | BTIG | Reiterated | Buy | $82 |
| 2026-07-15 | Mizuho | Target lowered | Outperform | $85 → $80 |
Total return (dividends reinvested) (ALC)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -6.9% | -12.2% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -7.0% | -2.6% |
| Volatility (annualized) | 28.4% | 26.9% |
| Max drawdown | -28.5% (Feb 2026→May 2026) | -36.7% (Sep 2024→May 2026) |
ALC suppliers, customers and competitors (named in its 20-F)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Lifecore Biomedical | “To ensure sufficient supply, we may determine that we need to provide financing to some suppliers, such as the financing arrangement with Lifecore Biomedical, Inc. we entered into in May 2023, which could increase our financial exposure.” |
| Competitor | Johnson & Johnson (JNJ) | “We primarily compete with Carl Zeiss Meditec AG, Bausch & Lomb Incorporated, Hoya Corporation, Glaukos Corporation and Johnson & Johnson in the surgical market.” |
| Competitor | AbbVie (ABBV) | “The vision care market is also highly competitive, and our primary competitors are Johnson & Johnson, Bausch & Lomb Incorporated and The Cooper Companies, Inc. In addition, AbbVie, Inc. (Allergan) is a competitor in ocular health.” |
Quoted from the company's 20-F filed Feb 24, 2026.
ALC analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.89 | $0.89 | +0.4% | $2.75B | 15 |
| Next quarter (ends Dec 2026) | $0.55 | $0.64 | -13.5% | $2.85B | 6 |
| Current fiscal year (ends Dec 2026) | $3.50 | $3.47 | +0.9% | $11.09B | 24 |
| Next fiscal year (ends Dec 2027) | $3.96 | $3.97 | -0.1% | $11.76B | 26 |
Key Statistics (as of October 23, 2026 at 10:01 UTC)
| Price | USD 70.63 |
|---|---|
| Change | ▲ 4.75% (up) |
| Previous Close | USD 67.43 |
| Open | USD 68.02 |
| Day Range | USD 68 – 70.68 |
| 52-Week Range | USD 61.84 – 87.64 |
| Volume | 2,207,898 shares |
| Market Cap | $34.14B |
| Exchange | NYQ |
Technical Analysis (ALC)
Nexqual's technical model rates ALC "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 10:01 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 65.45 (neutral) |
| vs SMA50 | Above (USD 68.02) |
| MACD | 0.25 (positive) |
Analyst Ratings (ALC)
Wall Street analysts rate ALC "Buy" based on 27 analysts, with a mean price target of USD 82.73 (range USD 62–103), per Nexqual as of October 23, 2026 at 10:01 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 27 |
| Mean Target | USD 82.73 |
| High Target | USD 103 |
| Low Target | USD 62 |
| Buy / Hold / Sell | 21 / 5 / 1 |
Earnings (ALC)
| Next Earnings Date | 2026-11-10 |
|---|---|
| EPS Estimate | USD 0.89 |
| Revenue Estimate | $2.75B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.84 vs est 0.76 ▲ beat |
| 2026-03-31 | USD 0.85 vs est 0.82 ▲ beat |
| 2025-12-31 | USD 0.78 vs est 0.87 ▼ miss |
| 2025-09-30 | USD 0.79 vs est 0.85 ▼ miss |
Source: Nexqual, October 23, 2026 at 10:01 UTC.
Financials & Fundamentals (ALC)
| Total Revenue | $10.86B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +8.70% |
| Gross Margin | +57.22% |
| Operating Margin | +14.63% |
| Profit Margin | +5.92% |
| ROE | +2.94% |
| Debt / Equity | 0.25 |
| Current Ratio | 2.09 |
| Total Cash | $1.46B |
| Total Debt | $5.30B |
Source: Nexqual, October 23, 2026 at 10:01 UTC.
Financial Health Score (ALC)
Nexqual rates Alcon Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 10:01 UTC.
| Growth | Mixed — Revenue +4.9% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 57%, operating 15% (last 12 months) |
| Balance Sheet | Strong — $1.46B cash vs $5.30B debt |
| Cash Flow | Solid — Operating cash flow $2.31B (TTM) |
| Efficiency | Weak — ROE 3%, ROA 2.8% |
Ownership (ALC)
| Insider Ownership | +0.20% |
|---|---|
| Institutional Ownership | +63.10% |
| Shares Outstanding | 483.40M |
| Float | 481.83M |
Source: Nexqual, October 23, 2026 at 10:01 UTC.
Leadership (ALC)
Alcon Inc. is led by David J. Endicott, CEO & Director, per Nexqual as of October 23, 2026 at 10:01 UTC.
| CEO & Director | David J. Endicott |
|---|---|
| Senior VP & CFO | Timothy C. Stonesifer |
| Senior VP & COO | Ian Bell |
| SVP of Global Research & Development and Chief Scientific Officer | Franck Leveiller |
| Senior VP & President of Americas | Leon Sergio Duplan Fraustro |
Major Backers & Investors (ALC)
Notable institutional backers of Alcon Inc. include NORGES BANK, Invesco, Aristotle Capital Management, LLC, according to Nexqual as of October 23, 2026 at 10:01 UTC.
Active Investors
| Investor | Stake |
|---|---|
| NORGES BANK | 2.2% |
| Invesco | 2.08% |
| Aristotle Capital Management, LLC | 2% |
| AKO Capital LLP | 1.94% |
| Zurcher Kantonalbank (Zurich Cantonalbank) | 1.58% |
| FMR, LLC | 1.53% |
| UBS Group AG | 1.43% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.95% |
| BNY Mellon | 2.61% |
| Amundi | 1.33% |
Source: Nexqual, October 23, 2026 at 10:01 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RMD | ResMed Inc. | USD 253.06 | ▲ 2.79% |
| WST | West Pharmaceutical Services, I | USD 394.03 | ▲ 0.14% |
| MDLN | Medline Inc. | USD 34.88 | ▼ 1.22% |
| BDX | Becton, Dickinson and Company | USD 200.42 | ▲ 3.13% |
| SOLV | Solventum Corporation | USD 87.45 | ▲ 0.9% |
| BAX | Baxter International Inc. | USD 25.65 | ▲ 3.85% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:01 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt